ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Takeda bets on Japan R&D hub for next blockbuster drug

Success of homegrown medicine key to Japanese company's global ambitions

Takeda President Christophe Weber announced an increase in R&D spending for the fiscal year ending March 2022. (Photo by Taro Yokosawa)

TOKYO -- Takeda Pharmaceutical's state-of-the-art research and development center in the waterfront city of Shonan has yet to yield a blockbuster treatment since its founding a decade ago -- a weak track record the Japanese drugmaker is determined to improve.

"The Shonan base has made a significant contribution to neuroscience," said Takashi Ichikawa, who heads the company's neuroscience research unit, on a conference call explaining Takeda's R&D efforts. "Shonan's pharmaceutical science level is recognized globally," he said.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more